Info: Read More
  • 中药标准品生产商,产品定制服务
  • 依普黄酮

    Ipriflavone

    依普黄酮
    产品编号 CFN70102
    CAS编号 35212-22-7
    分子式 = 分子量 C18H16O3 = 280.3
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Flavonoids
    植物来源
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    依普黄酮 CFN70102 35212-22-7 10mg QQ客服:1413575084
    依普黄酮 CFN70102 35212-22-7 20mg QQ客服:1413575084
    依普黄酮 CFN70102 35212-22-7 50mg QQ客服:1413575084
    依普黄酮 CFN70102 35212-22-7 100mg QQ客服:1413575084
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Universite Libre de Bruxelles (Belgium)
  • Yale University (USA)
  • Vin?a Institute of Nuclear Sciences (Serbia)
  • Universitas islam negeri Jakarta (Indonesia)
  • Nicolaus Copernicus Uniwersity (Poland)
  • Kyoto University (Japan)
  • Rio de Janeiro State University (Brazil)
  • University of Hull (United Kingdom)
  • Ain Shams University (Egypt)
  • Sanford Burnham Prebys Medical Discovery Institute (USA)
  • University of Canterbury (New Zealand)
  • Helmholtz Zentrum München (Germany)
  • Seoul National University (Korea)
  • Sri Ramachandra University (India)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Biomed Chromatogr.2016, 30(10):1573-81
  • Natural Product Communications2022, 7(3):1-7.
  • Food Bioscience2023, 52:102412
  • Processes2021, 9(11),2065.
  • South African J of Botany2020, 135:50-57
  • Korean J. Medicinal Crop Sci.2018, 26(2):148-156
  • Cytotechnology2022, s10616
  • J Food Sci.2021, 86(9):3810-3823.
  • J Agric Food Chem.2022, 70(51):16176-16187.
  • Legume Science2021, 3(4): e101.
  • Aquaculture2017, 481:94-102
  • J Cachexia Sarcopenia Muscle.2022, 13(6):3149-3162.
  • Process Biochemistry2019, 85:106-115
  • Foods.2020, 9(10):1348.
  • Phytomedicine.2019, 58:152893
  • Nutrients.2022, 14(16):3393.
  • Food Chem.2020, 327:126992.
  • LWT-Food Sci Technol2020, 109163
  • Regul Toxicol Pharmacol.2024, 149:105620.
  • Molecules.2021, 26(9):2791.
  • J Korean Society of Food Science & Nutrition2021, 50(9): 962-970
  • Int J Cosmet Sci.2023, 45(2):155-165.
  • Int J Mol Sci.2018, 19(9):E2681
  • ...
  • 生物活性
    Description: Ipriflavone plays a direct role in modulating the synthetic and growth properties of osteoblast‐like cells. Ipriflavone directly stimulates markers of the osteoblast phenotype at a certain stage in bone formation without affecting undifferentiated cells that have not been committed to the osteogenic lineage.
    In vitro:
    Journal of Bone & Mineral Research, 2010, 9(3):395-400.
    Effect of ipriflavone on expression of markers characteristic of the osteoblast phenotype in rat bone marrow stromal cell culture.[Pubmed: 8191934]
    The effects of ipriflavone on cellular proliferation and differentiation of osteoblasts were investigated using stromal cells isolated from the femoral bone marrow of young rats.
    METHODS AND RESULTS:
    To induce the formation of mineralized bone-like tissue in vitro, the cells were cultured in the presence of beta-glycerophosphate and dexamethasone. Ipriflavone was added when subculturing was started. After 14 days of culturing with ipriflavone (10(-7)-10(-5) M), increases in both the alkaline phosphatase activity and the hydroxyproline content per culture dish and a slight decrease in the saturated cell density were observed. Furthermore, continuous treatment with ipriflavone for 14-33 days resulted in an increase in the area of bone-like mineralized tissue accompanied by an increase in the secretion of osteocalcin. When culture medium lacking dexamethasone was used, rat bone marrow stromal cells neither differentiated into osteoblasts nor formed bone-like tissue, and under these conditions, ipriflavone had no effect on the proliferation or the phenotypic expression of the cells.
    CONCLUSIONS:
    These results suggest that ipriflavone directly stimulates markers of the osteoblast phenotype at a certain stage in bone formation without affecting undifferentiated cells that have not been committed to the osteogenic lineage.
    In vivo:
    Jama, 2001, 285(11):1482-8.
    Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.[Reference: WebLink]
    Data on the efficacy and safety of ipriflavone for prevention of postmenopausal bone loss are conflicting.To investigate the effect of oral ipriflavone on prevention of postmenopausal bone loss and to assess the safety profile of long-term treatment with ipriflavone in postmenopausal osteoporotic women.
    METHODS AND RESULTS:
    Prospective, randomized, double-blind, placebo-controlled, 4-year study conducted in 4 centers in Belgium, Denmark, and Italy from August 1994 to July 1998.Four hundred seventy-four postmenopausal white women, aged 45 to 75 years, with bone mineral densities (BMDs) of less than 0.86 g/cm(2).Patients were randomly assigned to receive ipriflavone, 200 mg 3 times per day (n = 234), or placebo (n = 240); all received 500 mg/d of calcium.Efficacy measures included spine, hip, and forearm BMD and biochemical markers of bone resorption (urinary hydroxyproline corrected for creatinine and urinary CrossLaps [Osteometer Biotech, Herlev, Denmark] corrected for creatinine), assessed every 6 months. Laboratory safety measures and adverse events were recorded every 3 months.Based on intent-to-treat analysis, after 36 months of treatment, the annual percentage change from baseline in BMD of the lumbar spine for ipriflavone vs placebo (0.1% [95% confidence interval (CI), -7.9% to 8.1%] vs 0.8% [95% CI, -9.1% to 10.7%]; P =.14), or in any of the other sites measured, did not differ significantly between groups. The response in biochemical markers was also similar between groups (eg, for hydroxyproline corrected for creatinine, 20.13 mg/g [95% CI, 18.85-21.41 mg/g] vs 20.67 mg/g [95% CI, 19.41-21.92 mg/g]; P =.96); urinary CrossLaps corrected for creatinine, 268 mg/mol (95% CI, 249-288 mg/mol) vs 268 mg/mol (95% CI, 254-282 mg/mol); P =.81. The number of women with new vertebral fracture was identical or nearly so in the 2 groups at all time points. Lymphocyte concentrations decreased significantly (500/microL (0.5 x 10(9)/L]) in women treated with ipriflavone. Thirty-one women (13.2%) in the ipriflavone group developed subclinical lymphocytopenia, of whom 29 developed it during ipriflavone treatment. Of these, 15 (52%) of 29 had recovered spontaneously by 1 year and 22 (81%) of 29 by 2 years.
    CONCLUSIONS:
    Our data indicate that ipriflavone does not prevent bone loss or affect biochemical markers of bone metabolism. Additionally, ipriflavone induces lymphocytopenia in a significant number of women.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.5676 mL 17.838 mL 35.6761 mL 71.3521 mL 89.1902 mL
    5 mM 0.7135 mL 3.5676 mL 7.1352 mL 14.2704 mL 17.838 mL
    10 mM 0.3568 mL 1.7838 mL 3.5676 mL 7.1352 mL 8.919 mL
    50 mM 0.0714 mL 0.3568 mL 0.7135 mL 1.427 mL 1.7838 mL
    100 mM 0.0357 mL 0.1784 mL 0.3568 mL 0.7135 mL 0.8919 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    菜豆素; Phaseollidin CFN98611 37831-70-2 C20H20O4 = 324.4 5mg QQ客服:2159513211
    拟人参皂苷Rh2; Pseudoginsenoside Rh2 CFN93178 1370264-16-6 C36H62O8 = 622.88 5mg QQ客服:215959384
    4-羟基间苯二甲酸; 4-Hydroxyisophthalic acid CFN70178 636-46-4 C8H6O5 = 182.1 20mg QQ客服:1413575084
    韧革菌素D; Vibralactone D CFN96454 1251748-32-9 C12H18O3 = 210.27 5mg QQ客服:1413575084

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产